Galapagos NV
GLPG
#5033
Rank
โ‚ฌ1.62 B
Marketcap
24,18ย โ‚ฌ
Share price
0.00%
Change (1 day)
1.41%
Change (1 year)

Revenue for Galapagos NV (GLPG)

Revenue in 2026 (TTM): โ‚ฌ1.04 Billion

According to Galapagos NV's latest financial reports the company's current revenue (TTM ) is โ‚ฌ1.06 Billion. In 2025 the company made a revenue of โ‚ฌ1.11 Billion an increase over the revenue in the year 2024 that were of โ‚ฌ0.27 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Galapagos NV from 2015 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚ฌ1.04 B-6.16%
2025 โ‚ฌ1.11 B303.5%
2024 โ‚ฌ0.27 B130.8%
2023 โ‚ฌ0.11 B-76.36%
2022 โ‚ฌ0.50 B4.21%
2021 โ‚ฌ0.48 B3.96%
2020 โ‚ฌ0.46 B-44.81%
2019 โ‚ฌ0.84 B192.55%
2018 โ‚ฌ0.28 B127.28%
2017 โ‚ฌ0.12 B-1.88%
2016 โ‚ฌ0.12 B227.37%
2015 โ‚ฌ39.56 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
โ‚ฌ84.01 B 7,758.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
โ‚ฌ39.35 B 3,580.82%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
โ‚ฌ53.32 B 4,887.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚ฌ48.35 B 4,423.05%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚ฌ57.34 B 5,263.59%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ52.69 B 4,829.00%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ38.50 B 3,501.77%๐Ÿ‡ฌ๐Ÿ‡ง UK
Fortress Biotech
FBIO
โ‚ฌ54.32 M-94.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ15.12 B 1,314.79%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel